Thymic tumors include thymic carcinoma, which exhibit aggressive behavior, and thymomas, which manifest a more indolent course. Complete resection is the mainstay of treatment, and there appears to be little benefit to partial resection. Postoperative radiotherapy may be useful in incompletely resected patients. Preoperative chemotherapy appears to increase the rate of complete resection and survival of patients with a stage III or IVa thymoma and should strongly be considered in such cases.
Histologic Classification

One can distinguish three groups of thymic tumors: (1) those with no cytologic features of malignancy [4 -6]; (2) an intermediate group, sometimes called welldifferentiated thymic carcinoma (WDTC)
, that have the organotypic features of thymomas but also have areas of atypia and occasional mitoses (usually Ͻ2 per 10 high-power field) [7, 8] ; and (3) thymic carcinomas (TC) that have abundant mitotic figures and other cytologic features of malignancy [9 -11] . It has been suggested these be called typical thymoma, atypical thymoma, and TC [12] .
Thymic carcinomas clearly represent a distinct, but small (Ͻ10%) group. These tumors occur in patients of all ages [9, 10, 13], are typically not associated with myasthenia gravis (MG) [7, 10, [13] [14] [15] , are frequently symptomatic because of the extent of local invasion [7, 10, 13] , and consistently exhibit much more aggressive behavior [9, 15] . Thymic carcinoma has been divided into subtypes, including squamous cell, mucoepidermoid, basaloid, lymphoepithelioma-like, small cell/ neuroendocrine, sarcomatoid, clear cell, and undifferentiated/anaplastic [10] . Thymic carcinoid tumors are generally classified as a type of TC, although some authors place them in a separate category of neuroendocrine tumors of the thymus [11] .
Whether WDTC should be recognized as a distinct group is controversial. The consistency of this classification among independent review by different pathologists is very high in one study [16] , but was found to be problematic in another [17] . Variability in how such tumors are classified is reflected by wide variations in the reported survival rates of this group as well as in the incidence of TC, which is less than 10% in some series [5, 18 -20] and about 30% (range, 18% to 41%) in others, apparently owing to the inclusion of WDTC [ The most recent classification system was proposed in 1999 by an international committee assembled by the World Health Organization (WHO) [11] . This system bears some similarities to the Mü ller-Hermelink system [28] Few studies have assessed the value of the WHO classification system as yet. One group found a correlation between the sequence of WHO histologic types and a progressively higher average tumor stage [29] . The same group subsequently reported a correlation with prognosis in a large cohort of 273 patients with long-term follow-up (significantly worse prognosis was seen for B3 types; TC were excluded) [24] . In fact, multivariate analysis in this study identified the WHO type as an independent prognostic factor along with Masaoka stage [24] . Another evaluation of the WHO system involving 90 patients found no prognostic differences among the A and B subtypes, but worse survival by univariate and multivariate analysis for type C (TC) [15] . However, the multivariate analysis is questionable because completeness of resection was excluded. Thus, the value of the WHO classification system over one separating thymoma, WDTC, and TC is unclear.
Some authors have applied the misleading term "benign thymoma" to bland thymomas that exhibit no gross evidence of invasion [ 
Clinical Presentation
The sex distribution of patients with a thymic tumor is roughly equal among series of more than 100 patients [ A widespread dogma proscribes a biopsy of a presumed thymic tumor out of concern of seeding the pleural space or the biopsy site [41] . However, there are few data to substantiate this. No case of seeding of a needle tract or biopsy site has ever been reported. Three instances of recurrence in a thoracotomy scar have been mentioned [51, 54] . A large series of 136 patients found a trend to better survival in those patients who underwent a preresection biopsy by multivariate analysis (p ϭ 0.056) [27] . The concern over pleural dissemination presumably stems from the observation that resected thymomas frequently recur as nodules throughout the parietal pleura [55] . However, this pattern of spread appears to be characteristic of thymoma itself rather than related to an operative procedure, because pleural nodules are also commonly seen (68%) in patients who present with advanced tumors, never having undergone a biopsy [ 
Treatment
Surgery
Surgical resection is the mainstay of treatment of thymomas, because the vast majority (90% to 95%) of these tumors are localized [2] . The reported operative mortality in series of more than 100 patients (spanning many decades) is an average of 2.5% (range, 0.7% to 4.9%) [ . This may reflect differences in the willingness of surgeons to undertake more extensive operations (eg, resection of the vena cava). Extended resections appear to be justified because complete resection is probably the most important prognostic factor (see subsequent section).
Survival
The 5-year overall survival rates after resection are quite good, even for patients with stage III and IV disease ( Table 2) . Overall survival at 15 years for stage I, II, III, and IV disease is reported as 78%, 73%, 30%, and 8%, respectively [18] . Not all patients with stage III or IV thymomas underwent a complete resection, even though they were probably carefully selected. Among surgical series of more than 100 patients, an average of 38% of deaths are related to thymoma (range, 19% to 58%), 9% to postoperative causes (range, 2% to 19%), 22% to MG (range, 16% to 27%), 9% to other autoimmune diseases (range, 2% to 19%), and 29% (range, 8% to 47%) to unrelated causes (including other cancers) [ Disease-free survival may be a better measure of the effectiveness of surgical treatment. Studies of more than 100 patients have found average disease-free survival rates at 10 years of 92%, 87%, 60%, and 35% for stages I, II, III, and IV, respectively [8, 18, 25, 31]. The best measure of outcome after resection may be the recurrence rate (Table 3 ). The recurrence rate for stage IV tumors shows wide variability, likely reflecting differences in selection and the small number of such patients in these reports. In general, recurrence rates are reported only for those patients in whom all gross tumor was removed.
The average time to recurrence is approximately 5 years (range, 3 to 7 years) [ 
Subtotal Resection
Although it is clear that every effort should be made to achieve a complete resection, it is controversial whether there is a benefit to carrying out a subtotal resection (debulking) when a complete resection cannot be accomplished. Some authors argue that a partial resection provides better survival than a simple biopsy in unre- It is difficult to compare the results of patients undergoing partial resection or biopsy only because of the possible influence of other treatments, selection bias, differences in the stage of thymomas among these patients, and differences in the follow-up periods. In addition, it is unclear how recurrence is defined in incompletely resected patients, or how much tumor removal constitutes a partial resection in most of these studies. With regard to this latter issue, the recurrence rate appears to be lower (36% versus 71%) after a resection that is microscopically incomplete (R 1 ) compared with a grossly incomplete resection (R 2 ) in one study of 28 patients, all of whom received adjuvant radiotherapy (RT) [57] . In summary, the data are unclear as to whether a partial resection is of benefit. In general, the difference in survival appears to be small, and may be explained entirely by selection bias. However, it is possible that an incomplete resection that leaves only a minimal amount of residual disease may yield a survival benefit, especially in the context of adjuvant therapy.
Prognostic Factors
By univariate analysis, stage has been widely found to correlate with prognosis ( [37] . All series addressing postoperative RT involve retrospective reviews spanning many decades, rather than an experience with a consistent treatment plan and selection criteria. To minimize any selection bias, the analysis presented here is limited to studies that reported outcomes separately by stage and completeness of resection (the two most consistent prognostic factors). Table 5 shows the results of retrospective series that have compared outcomes with and without adjuvant RT. In completely resected (R 0 ) patients, the recurrence rates for stage I thymomas are so low, even without adjuvant RT, that the use of RT is probably not justified. The value of RT in completely resected stage II and stage III patients is unclear. Although some series suggest a trend to a lower incidence of recurrence with adjuvant RT for stage II thymomas, the largest series by far found no differences [39] , and one of the larger series found the opposite result [ [34] . Adjuvant RT was also found to result in a lower recurrence rate among patients with incompletely resected stage IV thymomas (44% versus 75%; 13 patients) [34] . Finally, mediastinal recurrences have been found to be lower with RT among 26 stage III patients undergoing subtotal resection (5-year actuarial rate 21% versus 100%; no p value given) [38] . The use of RT in incompletely resected patients is also supported by very low rates of mediastinal failure among incompletely resected patients with gross residual disease who were treated with adjuvant RT (16% to 21%) [38, 60, 61] .
In summary, the role of adjuvant RT remains poorly defined. The benefit in stage I patients is marginal at best. Given the conflicting results and the potential selection bias in retrospective series, the role of adjuvant RT in completely resected stage II and stage III patients is unclear. It appears that RT does decrease the recurrence rate in incompletely resected patients.
Chemotherapy
Thymomas are sensitive to chemotherapy, with an objective response seen in an average of two thirds of patients (range, 10% to 100%), and a complete response in one third (range, 0% to 43%) [ The impact of chemotherapy on patient survival is difficult to assess. In a retrospective analysis, chemotherapy significantly reduced the rate of metastases to the lung, pleura, or distant sites (17% versus 38%; p Ͻ 0.05) among 90 patients with stage III or IV tumors who were treated with RT and either partial resection (34%) or no resection (61%) [25] . There was also a trend to better disease-free survival with chemotherapy among these patients (5-year survival 55% versus 32%, 10-year survival 41% versus 24%; not significant) [71] . In a much smaller study, no survival difference was seen whether or not chemotherapy was given in 19 patients with unresectable stage III thymomas (5-year survival 56% versus 58%) [22] . Treatment with somatostatin analogs (ie, octreotide) and prednisone has shown promise as a novel treatment approach in patients refractory to chemotherapy [72] .
In summary, although it is clear that a variety of chemotherapy regimens are active in thymomas, no conclusions can be drawn about the optimal regimen or the impact of treatment.
Preoperative Radiation
Preoperative RT has been used on a limited basis by some groups in patients thought to have thymomas invasive of other structures [ 37, 58, 73, 74] . The ability to carry out a complete resection in these patients has been reported to be 53%, 59%, and 75% [73, 74] , which can perhaps be compared with an average resectability rate in stage III thymomas of 50% in studies involving resection alone [ 1, 3, 18, 22, 31, 33, 38, 43] . The survival is not obviously better than that of other patients with locally advanced thymomas, with 10-year survival rates of 44% to 48% reported in two series (19 and 12 patients) Table 2 ). Most of these studies were controlled prospective trials, and do not appear to have excluded many patients with appropriately staged tumors at these institutions. There is no clear consensus on the best treatment approach for a thymoma that is deemed to be unresectable because the data are scant and uncontrolled. Overall, approximately one third of patients undergoing only a biopsy are alive 10 years later (Table 4) . 
Special Treatment Issues
Recurrence
Well-Differentiated Thymic Carcinoma
The survival of patients with WDTC has been reported to be variable, with 5-year survival rates ranging from 60% to 80% (average, 75%) and 10-year survival rates ranging from 30% to 78% (average, 61%) [ 
Thymic Carcinoma
The In a collected series of 81 cases, the 5-year and 10-year survival rates were 77% and 30%, respectively, among completely resected patients (n ϭ 53), 65% and 19%, respectively, after partial resection (n ϭ 11), and 28% and 0%, respectively, in unresectable patients (n ϭ 16) [82] . This is corroborated by a collected series of 50 patients, in which the 5-year and 10-year survival rates were 28% and 10%, respectively [87] . Dramatically better survival was reported in another series of 41 patients (10-year survival of approximately 75%, with no perceptible differences between stages) [39] . Multivariate analysis has found only unresectability and advanced stage to be associated with poorer survival, whereas sex, age, Cushing's syndrome, chemotherapy, RT, and recurrence had no impact [82] . Among smaller series survival appears to be better the lower the histologic grade (median survival, 9 to 11 years for low-grade tumors, 5 to 7 years for intermediate-grade tumors, and 1.5 to 3 years for high-grade tumors) [82, 87] .
Conclusion
Despite what is often an indolent course and a cytologically bland appearance, all thymic tumors can manifest malignant behavior. Classification schemes focusing on subtypes of bland tumors have questionable prognostic value, whereas distinguishing TC and perhaps also WDTC from bland thymomas is more useful. The frequent presence of associated parathymic conditions has engendered much interest, but does not affect the treatment of the thymoma itself. Biopsy of a mass suspected to be a thymoma is not detrimental, and should be done in cases in which the ability to achieve a complete resection with surgery alone or the diagnosis is unclear.
Surgery continues to be the mainstay of treatment, and the ability to accomplish a complete resection appears to be the most important prognostic factor. Therefore, every effort must be made at the time of resection to achieve this. There appears to be little, if any, benefit of partial resection (debulking). Thymomas also have a high response rate to chemotherapy or RT. The value of postoperative (adjuvant) RT in completely resected stage II or III tumors appears to be unclear at best, whereas the data suggest a benefit in patients who are incompletely resected. Multimodality therapy involving preoperative chemoradiotherapy appears to increase the rate of complete resection of stage III and IVa thymomas. Because the ability to achieve a complete resection results in excellent long-term survival of even advanced stage tumors, a multimodality approach should strongly be considered in such cases. A recurrence should be completely resected whenever possible, because this approach is associated with good long-term survival.
